Pegylated interferon α-2a(Peg-IFN-α) not only inhibit viral replication, but also play an important role in immune regulation, while Nucleoside analog(ue) drugs only inhibit viral replication. In hepatitis B infection, cytokines played a vital role. This study was aimed at investigating the changes of cytokines during Peg-IFN-αand nucleoside analog(ue) therapy.Meanwhile, the investigators wanted to verify whether Peg-IFN-α therapy resulted in the secretion of cytokines.
Pegylated interferon α-2a(Peg-IFN-α)and Nucleoside analog(ue) drugs can inhibit viral replication , but Peg-IFN-α also play an important role in immune regulation . In hepatitis B infection, cytokines including Fit-3L, IFN-alpha2, IFN-gama, IL-10, IL-17A,IL-2, IL-6, TNF-alpha, TGF-beta1, TGF-beta2,TGF-beta3, played a vital role.Peg-IFN-α recommended as the first-line treatment has a higher chance to achieve HBeAg seroconversion and even HBsAg disappearance than nucleoside analog(ue) drugs, which might be related to the increase of cytokine secretion in the case of hepatitis and during Peg-IFN-α therapy.This study was aimed at investigating the changes of cytokines during Peg-IFN-αand nucleoside analog(ue) therapy.Meanwhile, the investigators wanted to clarify whether Peg-IFN-α therapy led to the secretion of cytokines.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
120
patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
Beijing Ditan hospital,Capital Medical University
Beijing, Beijing Municipality, China
RECRUITINGthe changes of cytokines
the changes of cytokines levels will be measured by Luminex test after Pegylated Interferon α-2a and entecavir((ETV) Treatment 24 weeks.
Time frame: after treatment 24 weeks
the change of HBVDNA levels (IU/ML)
the curative effect of antiviral therapy will be evaluated by HBV DNA levels
Time frame: afte treatment 48 weeks
the change of ALT levels(U/L)
the curative effect of antiviral therapy will be evaluated by ALT levels
Time frame: afte treatment 48 weeks
the change of AST levels(U/L)
the curative effect of antiviral therapy will be evaluated by AST levels
Time frame: afte treatment 48 weeks
the change of HBsAg levels (IU/ML)
the curative effect of antiviral therapy will be evaluated by HBsAg levels
Time frame: afte treatment 48 weeks
the change of HBeAg levels (IU/ML)
the curative effect of antiviral therapy will be evaluated by HBeAg levels
Time frame: afte treatment 48 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.